Regeneron Pharmaceuticals Catalent's Indiana site, linked with Regeneron's high-dose Eylea rejection, dinged with 3 FDA observations
Regeneron Pharmaceuticals Regeneron Pharmaceuticals, Inc. to Post FY2024 Earnings of $33.17 Per Share, Cantor Fitzgerald Forecasts (NASDAQ:REGN)
Regeneron Pharmaceuticals Causaly, an AI platform for drug discovery and biomedical research, raises $60M
Regeneron Pharmaceuticals Causaly Raises $60 Million in Series B Funding to Catalyze AI-powered Preclinical Discovery
Regeneron Pharmaceuticals Sanofi goes 'all in' on AI with new app to support company's manufacturing, R&D and more
